Clinical trial
A Randomized Phase II Pharmacokinetics/Pharmacodynamics Study of Epratuzumab in Patients With Systemic Lupus Erythematosus
NCT00113971 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase II Pharmacokinetics/Pharmacodynamics Study of Epratuzumab in Patients With Systemic Lupus Erythematosus
- Lead sponsor
- UCB Pharma
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- April 30, 2005
- Completion date
- June 30, 2007
- Enrollment
- 20
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.